Skip to main content

Table 1 Patient characteristics and antifungal prophylaxis regimen

From: Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study

Characteristic PAP (N = 818) SAP (N = 88) Non-antifungal prophylaxis (n = 147)
Age, mean (range/%)/case 28.5 (1–63) 32.2 2–58) 29.6 (4–61)
 0–6 33 (4 %) 3 (3.4 %) 4 (2.7 %)
 >6–16 129 (15.8 %) 10 (11.4 %) 20 (13.6 %)
 >16–40 488 (59.7 %) 49 (55.7 %) 85 (57.8 %)
 >40–65 168 (20.5 %) 26 (29.5 %) 38 (25.9 %)
Gender
 Male 505 (61.7 %) 51 (58.0 %) 87 (59.2 %)
 Female 313 (38.3 %) 37 (42.0 %) 60 (40.8 %)
E-COG
 0 227 (27.8 %) 18 (20.5 %) 48 (32.7 %)
 1 438 (53.5 %) 54 (61.4 %) 74 (50.3 %)
 2 89 (10.9 %) 11 (12.5 %) 17 (11.6 %)
 3 51 (6.2 %) 5 (5.7 %) 7 (4.8 %)
 4 13 (1.6 %) 1 (0.7 %)
Underlying disease
 Acute myeloid leukemia 289 (35.3 %) 44 (50.0 %) 43 (29.3 %)
 Acute lymphocytic leukemia 241 (29.5 %) 32 (36.4 %) 37 (25.2 %)
 Chronic myeloid leukemia 100 (12.2 %) 3 (3.4 %) 23 (15.6 %)
 Aplastic anemia 69 (8.4 %) 13 (8.8 %)
 Myelodysplastic syndrome 62 (7.6 %) 2 (2.3 %) 16 (10.9 %)
 Non-Hodgkin’s lymphoma 23 (2.8 %) 4 (4.5 %) 4 (2.7 %)
 Chronic lymphocytic leukemia 4 (0.5 %)
 Multiple myeloma 2 (0.2 %) 1 (0.7 %)
 Hodgkin’s disease 2 (0.2 %) 3 (2.0 %)
 Myeloprolififerative neoplasms 2 (0.2 %)
 Solid tumor 1 (0.1 %)
 Hereditary and metabolic disorders 9 (1.1 %)
 Paroxysmal nocturnal hemoglobinuria 1 (0.1 %) 1 (0.7 %)
 Othersa 13 (1.6 %) 3 (3.4 %) 6 (4.1 %)
Transplantation type
 HLA-matched related (sibling) 335 (41.0 %) 35 (39.8 %) 77 (52.4 %)
 Haploidentical 269 (32.9 %) 26 (29.5 %) 35 (23.8 %)
 Unrelated 213 (26.0 %) 27 (30.7 %) 35 (23.8 %)
Source of stem cells
 PB 417 (51.0 %) 67 (76.1 %) 105 (71.4 %)
 BM + PB 348 (42.5 %) 19 (21.6 %) 20 (13.6 %)
 BM 33 (4.0 %) 7 (4.8 %)
 CB 15 (1.8 %) 1 (1.1 %) 3 (2.0 %)
 BM + CB 3 (0.4 %)
 BM + PB + CB 2 (0.2 %) 1 (1.1 %) 8 (5.4 %)
Conditioning regimen
 Myeloablative
  Yes 729 (89.1 %) 83 (94.3 %) 124 (84.4 %)
  No 89 (10.9 %) 5 (5.7 %) 23 (15.6 %)
 Total body radiotherapy
  Yes 122 (14.9 %) 23 (26.1 %) 13 (8.8 %)
  No 696 (85.1 %) 65 (73.9 %) 134 (91.2 %)
Antithymocyte globulin
 Yes 516 (63.1 %) 52 (59.1 %) 64 (43.5 %)
 No 302 (36.9 %) 36 (40.9 %) 83 (56.5 %)
Concomitant disease 137 (16.7 %) 22 (25.0 %) 23 (15.6 %)
 Cardiovascular disease 24 (2.9 %) 2 (2.3 %) 4 (2.7 %)
 Diabetes 24 (2.9 %) 2 (2.3 %) 6 (4.1 %)
 Viral hepatitis 22 (2.7 %) 9 (10.2 %) 4 (2.7 %)
 CMV infection 1 (0.1 %) 2 (2.3 %) 1 (0.7 %)
 Tuberculosis 14 (1.7 %) 3 (3.4 %) 2 (1.4 %)
 Autoimmune diseases 9 (1.1 %) 1 (1.1 %)
 Othersb 61 (7.5 %) 5 (5.7 %) 8 (5.4 %)
aGVHD    
 I–II aGVHD 257 (31.4 %) 27 (30.7 %) 40 (27.2 %)
 III–IV aGVHD 57 (7.0 %) 7 (8.0 %) 15 (10.2 %)
cGVHD
 Limited 57 (7.0 %) 9 (10.3 %) 10 (6.85)
 Extensive 24 (2.9 %) 2 (2.3 %) 4 (2.7 %)
Drugs for IFD prophylaxis
 Single drug 667 (81.5 %) 69 (78.4 %)
  Fluconazole 429 (64.3 %) 8 (11.6 %)
  Itraconazole 103 (15.4 %) 17 (24.6 %)
  Voriconazole 71 (10.6 %) 32 (46.4 %)
  Caspofungin 4 (0.6 %) 6 (8.7 %)
  Amphotericin B 2 (0.3 %) 1 (1.4 %)
 Drug combination 151 (18.5 %) 19 (21.6 %)
Route of administration
 Oral 466 (57.0 %) 29 (33.0 %)
 Intravenous 214 (26.2 %) 37 (42.0 %)
 Oral + intravenous 138 (16.9 %) 22 (25.0 %)
Time of prophylaxis before HSCT mean (SD), days 10.8 (6.57) 12.0 (6.43)
  1. E-COG Eastern Cooperative Oncology Group, PAP primary antifungal prophylaxis, SAP secondary antifungal prophylaxis, BM bone marrow, PB peripheral blood, CB cord blood, CMV cytomegalovirus, aGVHD acute graft versus host disease, cGVHD chronic graft versus host disease, IFD invasive fungal diseases, HSCT hematopoietic stem cell transplantation
  2. aOthers include chronic myelomonocytic leukemia (n = 3), T lymphoblastic lymphoma leukemia (n = 2), mixed-lineage leukemia (n = 10), aggressive NK cell leukemia (n = 3), myeloid sarcoma (n = 1), plasmablasticlymphoma (n = 3)
  3. bOthers include infectious disease (n = 18), digestive system diseases (n = 10), cholecystolithiasis (n = 7), mouth disease (n = 8), urological diseases (n = 6), intestinal diseases (n = 7), endocrine diseases (n = 7), surgery (n = 5), cerebrovascular disease (n = 4), tumor (n = 2)